Buyout Watch #8 – Five Biotech Stocks in Focus: ABVX, VKTX, BCRX, MIRM and KRYS

Buyout Watch #8 – Five Biotech Stocks in Focus: ABVX, VKTX, BCRX, MIRM and KRYS

Today’s Buyout Watch

Large drugmakers often acquire biotech companies to add a promising medicine, commercial product, or specialized technology to their pipelines. That can make certain companies interesting to watch—but a potential strategic fit does not mean a buyer is interested or that a deal will happen.

This edition looks at five biotech companies that have drawn attention in takeover-target coverage: Abivax, Viking Therapeutics, BioCryst Pharmaceuticals, Mirum Pharmaceuticals, and Krystal Biotech.

Important: No acquisition offer is confirmed for any company discussed here. The offer ranges are hypothetical examples based on each stock’s October 29, 2026 price and an assumed acquisition premium. They are not predictions of where the shares will trade.

---

1. Abivax SA (NASDAQ: ABVX)

The Buyout Case

Abivax is developing obefazimod, an oral treatment for ulcerative colitis. Its Phase 3 maintenance study reported positive results, and the company expects to submit an FDA application in the fourth quarter of 2026. A successful regulatory filing and eventual approval could make the company’s program more attractive to a pharmaceutical company looking to expand its inflammation and immunology business.

Abivax has also been the subject of acquisition speculation involving Eli Lilly. However, those reports have not established that a deal is underway, and Abivax’s CEO previously dismissed takeover talk as “noise.” Investors should treat the rumor history as context, not confirmation.

Hypothetical offer range: $111–$125 per share
Illustrative midpoint target: $118 per share
Time horizon: 6–18 months

This scenario assumes a buyer would pay a premium to the October 29 share price of about $89. The potential value would depend heavily on the FDA filing, the data package, commercial prospects, and the buyer’s view of obefazimod’s risks.

What Could Change the Picture?

• Submission and review of the planned FDA application

• Regulatory feedback and the timing of a potential decision

• Further clinical data, including the Crohn’s disease program

• Whether any company confirms discussions or an offer

• Competition from existing and developing ulcerative-colitis treatments

My ABVX Buyout Watch: A late-stage drug candidate and prior takeover speculation put ABVX on the watchlist, but no confirmed buyer or transaction exists.

---

2. Viking Therapeutics, Inc. (NASDAQ: VKTX)

The Buyout Case

Viking is developing treatments for metabolic and endocrine disorders, including VK2735 for obesity. The company has advanced injectable VK2735 into Phase 3 and initiated a Phase 3 program for the oral formulation in October 2026. Its programs give a potential acquirer exposure to the obesity market, though the products remain investigational and must still establish safety and effectiveness in larger studies.

A larger drugmaker might find Viking’s development programs and metabolic pipeline strategically useful. At the same time, the high cost of obesity-drug development and the strength of existing competitors could make an acquisition difficult to justify.

Hypothetical offer range: $35–$40 per share
Illustrative midpoint target: $37 per share
Time horizon: 12–24 months

This scenario uses an assumed premium to the October 29 share price of about $27. It assumes the clinical programs continue to advance and that a buyer sees enough value to acquire the company before key development risks are resolved.

What Could Change the Picture?

• Progress and results from the Phase 3 injectable and oral programs

• Safety, tolerability, and weight-loss results in larger trials

• Manufacturing and commercialization requirements

• Competition from established obesity-drug makers

• Whether Viking pursues a partnership, licensing deal, or standalone development

My VKTX Buyout Watch: VKTX has a high-profile area of research and active late-stage development, but its value remains closely tied to future clinical results.

---

3. BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

The Buyout Case

BioCryst has a commercial rare-disease business built around ORLADEYO, an oral treatment to prevent hereditary angioedema attacks. The FDA approved an ORLADEYO oral-pellet formulation for adults and adolescents in October 2026, expanding the available administration options.

BioCryst is also developing navenibart, a longer-acting investigational treatment for hereditary angioedema. A larger rare-disease company could see value in combining BioCryst’s existing commercial product, patient and prescriber relationships, and development pipeline with its own portfolio.

Hypothetical offer range: $11–$12.50 per share
Illustrative midpoint target: $11.75 per share
Time horizon: 12–24 months

This scenario applies an assumed premium to the October 29 share price of about $8.50. A buyer’s valuation would depend on ORLADEYO’s future sales, competition, the navenibart data, and the company’s financial outlook.

What Could Change the Picture?

• ORLADEYO sales growth and the commercial effect of the new formulation

• Clinical progress and results for navenibart

• BioCryst’s upcoming quarterly financial results

• Competitive developments in hereditary angioedema

• Whether the company expands its portfolio through partnerships or acquisitions

My BCRX Buyout Watch: BioCryst offers an established rare-disease product and additional pipeline opportunities, while competition and future product results remain important risks.

---

4. Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)

The Buyout Case

Mirum has a commercial rare-disease portfolio and several programs addressing liver and other serious conditions. In its second-quarter 2026 update, the company reported $176.2 million in global product sales and raised its full-year product-sales guidance to $680 million–$700 million. In October, Mirum also reported that its Phase 3 EXPAND study of LIVMARLI met its primary endpoint in ultra-rare cholestatic liver diseases.

Those commercial results and clinical programs could interest a larger pharmaceutical company seeking rare-disease revenue and additional products. The company also has programs at different stages, giving a potential buyer several sources of possible future value.

Hypothetical offer range: $108–$121 per share
Illustrative midpoint target: $115 per share
Time horizon: 6–18 months

This scenario uses an assumed premium to the October 29 share price of about $86. The range depends on whether sales growth continues, whether clinical results translate into approvals, and how a buyer values the company’s existing and potential products.

What Could Change the Picture?

• Continued sales growth across Mirum’s commercial products

• Results and regulatory plans for LIVMARLI and other programs

• The company’s next quarterly financial update

• Development timelines and costs for its pipeline

• Whether a larger rare-disease company shows interest in a transaction

My MIRM Buyout Watch: Mirum combines commercial revenue with multiple development programs, but a buyer would still need to assess execution, regulatory, and product risks.

---

5. Krystal Biotech, Inc. (NASDAQ: KRYS)

The Buyout Case

Krystal Biotech’s VYJUVEK is a commercial gene therapy for dystrophic epidermolysis bullosa. In its second-quarter 2026 report, the company said VYJUVEK generated $119.2 million in global product revenue, up 24% from the prior-year quarter. Krystal also reported a strong cash and investment balance and continued international expansion plans.

A large biotechnology or pharmaceutical company could value Krystal’s commercial product, its gene-therapy capabilities, and the opportunity to expand VYJUVEK’s reach. But Krystal’s size and financial resources could also make it more likely to continue operating independently rather than accept a buyout.

Hypothetical offer range: $389–$438 per share
Illustrative midpoint target: $410 per share
Time horizon: 12–24 months

This scenario applies an assumed premium to the October 29 share price of about $325. The hypothetical premium reflects the company’s growing commercial business and platform potential; it does not mean that an offer is expected.

What Could Change the Picture?

• VYJUVEK sales growth and reimbursement access

• International launch progress

• Results from the company’s other development programs

• Continued cash generation and financial performance

• Whether a buyer could justify the cost of acquiring a company with a growing commercial product

My KRYS Buyout Watch: Krystal has a commercial gene-therapy product and expanding sales, though its scale and growth prospects may support continued independence.

---

Today’s Buyout Watch Ranking

This ranking reflects the strength of the potential strategic case and the developments to monitor. It is not a ranking of expected stock performance.

🥇 ABVX — Late-stage ulcerative-colitis program and prior takeover speculation

🥈 MIRM — Commercial growth and several clinical programs

🥉 BCRX — Established rare-disease product and expanding ORLADEYO options

4. VKTX — High-profile obesity programs, with significant clinical risk

5. KRYS — Growing commercial gene-therapy business, though a buyout could be costly

---

My Takeaway

These five companies offer different possible acquisition stories. ABVX and VKTX are tied closely to the progress of investigational medicines. BCRX and MIRM combine commercial products with additional development programs. KRYS has a growing gene-therapy business that may be valuable to a larger company, but its size could make a transaction expensive.

The price ranges in this post are hypothetical offer scenarios based on assumed premiums to the October 29, 2026 share prices. They are not analyst price targets, forecasts, or evidence of negotiations. A company can be a plausible strategic fit and still never receive an offer.

For investors, the key questions are whether the businesses can keep advancing their products, what those products may be worth commercially, and whether a potential buyer would see enough value to make an offer.

Continue Your Research 

Explore Buyout Watch

Visit the Trading Academy

Browse Biotech Catalyst Watch

Browse OTC Buzz Tracker

---

Investment Disclaimer

This analysis is provided solely for educational, informational and entertainment purposes and represents my personal research and opinion.

Nothing published on Ask Warren HQ constitutes financial, investment, tax, legal or accounting advice or a recommendation to buy, sell or hold any security.

Biotechnology stocks can be highly volatile and involve clinical, regulatory, commercial, financing, and competitive risks. A potential acquisition is uncertain, and investors should not make decisions based on unconfirmed rumors or hypothetical offer scenarios.

Always conduct your own independent research and consider consulting a qualified financial professional before making investment decisions.